Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Markus Axelsson"'
Autor:
Lenka Novakova, Anna Karin Hedström, Markus Axelsson, Anne Frandsen Brandt, Lars Alfredsson, Tomas Olsson, Jan Lycke
Publikováno v:
Brain and Behavior, Vol 14, Iss 3, Pp n/a-n/a (2024)
Abstract Background A significant proportion of individuals with suspicious onset of multiple sclerosis (MS) does not fulfill the diagnostic criteria. Although some receive other diagnoses, many remain undiagnosed and lack healthcare follow‐up. Thi
Externí odkaz:
https://doaj.org/article/fc59ed666d324f91830d1944a59b9bee
Autor:
Sofia Sandgren, Lenka Novakova, Anna Nordin, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is a pulsed immune reconstitution therapy for multiple sclerosis (MS).ObjectiveTo assess basic characteristics, therapeutic effects, and prognostic biomarkers on clinical and imaging parameters of disease activity for rela
Externí odkaz:
https://doaj.org/article/1a51aa49d87b4da59edc2051d2fd6490
Autor:
Magnus Johnsson, Fredrik Asztely, Susanne Hejnebo, Markus Axelsson, Clas Malmeström, Torbjörn Olausson, Jan Lycke
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 9, Iss 8, Pp 1296-1301 (2022)
Abstract SARS‐COV‐2 frequently cause neurological disorders and is sometimes associated with onset of autoimmune diseases affecting the nervous system. Over recent years, a rare but distinct diagnosis designated myelin oligodendrocyte glycoprotei
Externí odkaz:
https://doaj.org/article/7ac733ed610b493fae51ca6944200cbe
Autor:
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, Ingrid Kockum, Tomas Olsson, Clas Malmestrom, Jan Lycke
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundAlemtuzumab (ALZ) is an immune reconstitution therapy for treating relapsing-remitting multiple sclerosis (RRMS). However, ALZ increases the risk of secondary autoimmune diseases (SADs).ObjectiveWe explored whether the detection of autoimmu
Externí odkaz:
https://doaj.org/article/57d02a89c1f745458ba0c6a29dfd6ed3
Autor:
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Sofia Rasch, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundEvolving evidence suggests that measurement of cerebrospinal fluid (CSF) kappa free light chain (KFLC) synthesis has high diagnostic sensitivity and specificity for multiple sclerosis (MS), but its prognostic ability is less investigated. T
Externí odkaz:
https://doaj.org/article/22580cb307b44a869eff8346adbec0e9
Autor:
Igal Rosenstein, Sofia Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundEmerging evidence supports that determination of intrathecal immunoglobulin M (IgM) synthesis (ITMS) and neurofilament light (NfL) concentration in cerebrospinal fluid (CSF) may be clinically useful as disease severity biomarkers in relapsi
Externí odkaz:
https://doaj.org/article/b3805a9ddeac443699809381360d79eb
Autor:
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat, Antoine Leuzy, Emma L. van der Ende, Thomas K. Karikari, Andrea L. Benedet, Tharick A. Pascoal, Alberto Lleó, Lucilla Parnetti, Daniela Galimberti, Laura Bonanni, Andrea Pilotto, Alessandro Padovani, Jan Lycke, Lenka Novakova, Markus Axelsson, Latha Velayudhan, Gil D. Rabinovici, Bruce Miller, Carmine Pariante, Naghmeh Nikkheslat, Susan M. Resnick, Madhav Thambisetty, Michael Schöll, Gorka Fernández-Eulate, Francisco J. Gil-Bea, Adolfo López de Munain, Ammar Al-Chalabi, Pedro Rosa-Neto, Andre Strydom, Per Svenningsson, Erik Stomrud, Alexander Santillo, Dag Aarsland, John C. van Swieten, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Abdul Hye, Oskar Hansson
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Cerebrospinal fluid neurofilament light (NfL) is a biomarker for neurodegeneration that can also be assessed in blood. Here the authors show in a validation study the potential for plasma NfL as a biomarker for several neurodegenerative diseases.
Externí odkaz:
https://doaj.org/article/5a53b0a732414b4ca05246e46c25baa3
Autor:
Sofia Thunström, Markus Axelsson
Publikováno v:
BMC Neurology, Vol 19, Iss 1, Pp 1-4 (2019)
Abstract Background Missense mutations in SAMD9L gene is associated with ataxia-pancytopenia syndrome (ATXPC), OMIM#159550. Common clinical features in these patients include neurological and hematological symptoms. The phenotype and age of onset is
Externí odkaz:
https://doaj.org/article/824377cbc2d141eea51a6e82cf42e8d2
Autor:
Linn Hermansson, Aylin Yilmaz, Markus Axelsson, Kaj Blennow, Dietmar Fuchs, Lars Hagberg, Jan Lycke, Henrik Zetterberg, Magnus Gisslén
Publikováno v:
Journal of Neuroinflammation, Vol 16, Iss 1, Pp 1-9 (2019)
Abstract Background HIV-1 infects the central nervous system (CNS) shortly after transmission. This leads to a chronic intrathecal immune activation. YKL-40, a biomarker that mainly reflects activation of astroglial cells, has not been thoroughly inv
Externí odkaz:
https://doaj.org/article/a7dde4bd64794be9905b3acf5023678e
Publikováno v:
Brain and Behavior, Vol 9, Iss 11, Pp n/a-n/a (2019)
Abstract Objectives Immunotherapy in addition to antiepileptic drugs can improve seizure freedom rates in autoimmune epilepsy, highlighting the importance of early diagnosis. A diagnosis of autoimmune epilepsy can be supported by presence of serum an
Externí odkaz:
https://doaj.org/article/135895d14b5840dc9295a5f7f708d372